Canadian Weed!

[JohnCM]

Outstanding Shares
3,534,810
01/12/2021

The following appears to be a boatload of "hot air."

OTC DISCLOSURE & NEWS SERVICE

Lexaria Announces Effective Date for Reverse Stock SplitPress Release | 01/08/2021
Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECHPress Release | 12/22/2020
Lexaria Closes Sale of Non-Pharmaceutical THC-Related AssetsPress Release | 12/10/2020
Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor ConferencesPress Release | 12/07/2020
Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral DrugsPress Release | 12/01/2020
Lexaria Bioscience Sells Non-Pharmaceutical THC-Related Assets for CDN$3.85MPress Release | 11/19/2020
Lexaria Bioscience Advances 2021 Strategic InitiativesPress Release | 11/05/2020
Lexaria Bioscience Extends Warrant TermPress Release | 10/26/2020
Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than ExpectedPress Release | 10/22/2020
Lexaria Bioscience Granted First European Patent for DehydraTECH TechnologyPress Release | 10/21/2020
Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECH Technology in Delivering Antiviral DrugsPress Release | 09/29/2020
Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD PowdersPress Release | 09/23/2020
Lexaria Bioscience Continues to Grow its Patent PortfolioPress Release | 09/22/2020
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners CorporationPress Release | 09/16/2020
DGAP-News: Lexaria Bioscience Corp.: Lexaria Bioscience announces R&D agreement with British American TobaccoPress Release | 09/01/2020
Lexaria Bioscience Announces R&D Agreement With British American TobaccoPress Release | 08/31/2020
Lexaria Bioscience to Present at the LD 500 Virtual ConferencePress Release | 08/20/2020
Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure ReductionPress Release | 07/28/2020
Lexaria BioScience Files Application with Senior U.S. Stock Exchange for UplistingPress Release | 07/21/2020
DGAP-News: Altria and Lexaria Conclude Phase I Research and Development ProgramPress Release | 07/16/2020